Two Studies Map How Protein Patterns in Melanoma Tumors Affect Treatment Response

Researchers were also able to classify tumors into three different subtypes with a high degree of accuracy.

Key Highlights

  • Two studies in Cancer Discovery and Clinical Cancer Research examined tumor proteins to better understand melanoma immunotherapy outcomes.
  • A molecular atlas identified protein alterations associated with patient survival and potential targets for future drugs.
  • Analysis of 208 pretreatment tumor samples revealed immune-rich, proliferative, and growth-and-metastasis subtypes.
  • A classifier based on protein patterns predicted immunotherapy response type and progression-free survival.

Two studies published in Cancer Discovery and Clinical Cancer Research examined how protein patterns in melanoma tumors can predict how patients will respond to immunotherapy and can help find promising biomarkers and drug targets.

Immune checkpoint inhibitors are a type of cancer immunotherapy that many patients end up not responding to. It hasn't been clear which patients will or will not respond, however. Researchers studied the proteome, which is the complete set of proteins made by cells in a tissue, to find answers. This contributed to making a "molecular atlas," which identifies chemical alterations to proteins linked to patient survival, along with potential targets for future drugs.

Additionally, the second study analyzed 208 tumor samples collected prior to immunotherapy. Researchers identified three tumor subtypes based on distinct protein patterns as a result: an immune-rich group; a proliferative group with elevated features of cell growth; and a growth and metastasis group with characteristics tied to tumor spread. 

The researchers then trained a classifier model to sort tumors into those three groups based on protein patterns. The model was able to predict treatment response type and progression-free survival with a high degree of certainty. 

About the Author

Matt MacKenzie

Matt MacKenzie

Associate Editor

Matt MacKenzie is Senior Staff Writer and Associate Editor of Healthcare Purchasing News (HPN), where he leads daily news coverage and contributes in-depth features on healthcare supply chain, sterile processing, infection prevention and clinical operations. Through industry reporting and expert interviews, he examines the trends, technologies and operational challenges shaping healthcare purchasing and patient care. 

Sign up for our eNewsletters
Get the latest news and updates